Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning
Top Cited Papers
- 28 June 2002
- journal article
- clinical trial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 296 (5577) , 2410-2413
- https://doi.org/10.1126/science.1070104
Abstract
Hematopoietic stem cell (HSC) gene therapy for adenosine deaminase (ADA)–deficient severe combined immunodeficiency (SCID) has shown limited clinical efficacy because of the small proportion of engrafted genetically corrected HSCs. We describe an improved protocol for gene transfer into HSCs associated with nonmyeloablative conditioning. This protocol was used in two patients for whom enzyme replacement therapy was not available, which allowed the effect of gene therapy alone to be evaluated. Sustained engraftment of engineered HSCs with differentiation into multiple lineages resulted in increased lymphocyte counts, improved immune functions (including antigen-specific responses), and lower toxic metabolites. Both patients are currently at home and clinically well, with normal growth and development. These results indicate the safety and efficacy of HSC gene therapy combined with nonmyeloablative conditioning for the treatment of SCID.Keywords
This publication has 20 references indexed in Scilit:
- Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 DiseaseScience, 2000
- Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined ImmunodeficiencyNew England Journal of Medicine, 1999
- An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populationsJournal of Immunological Methods, 1996
- Human T- and B-cell functions in SCID-hu miceSeminars in Immunology, 1996
- Hepatic Dysfunction as a Complication of Adenosine Deaminase DeficiencyNew England Journal of Medicine, 1996
- T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 YearsScience, 1995
- Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA − Immunodeficient PatientsScience, 1995
- High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells.The Journal of Experimental Medicine, 1994
- Transfer of the ADA Gene into Bone Marrow Cells and Peripheral Blood Lymphocytes for the Treatment of Patients Affected by ADA-Deficient SCIDHuman Gene Therapy, 1993
- Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients.Journal of Clinical Investigation, 1981